Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Depreciation and Depletion (2019 - 2024)

Historic Depreciation and Depletion for Allogene Therapeutics (ALLO) over the last 6 years, with Q1 2024 value amounting to $3.6 million.

  • Allogene Therapeutics' Depreciation and Depletion rose 136.87% to $3.6 million in Q1 2024 from the same period last year, while for Mar 2024 it was $14.2 million, marking a year-over-year increase of 97.09%. This contributed to the annual value of $14.2 million for FY2023, which is 67.16% down from last year.
  • Latest data reveals that Allogene Therapeutics reported Depreciation and Depletion of $3.6 million as of Q1 2024, which was up 136.87% from $3.5 million recorded in Q4 2023.
  • In the past 5 years, Allogene Therapeutics' Depreciation and Depletion ranged from a high of $4.2 million in Q4 2021 and a low of $1.8 million during Q3 2020
  • Over the past 5 years, Allogene Therapeutics' median Depreciation and Depletion value was $3.5 million (recorded in 2023), while the average stood at $2.9 million.
  • Per our database at Business Quant, Allogene Therapeutics' Depreciation and Depletion soared by 24797.79% in 2020 and then plummeted by 2767.56% in 2022.
  • Quarter analysis of 5 years shows Allogene Therapeutics' Depreciation and Depletion stood at $1.8 million in 2020, then soared by 130.04% to $4.2 million in 2021, then decreased by 27.68% to $3.1 million in 2022, then grew by 13.33% to $3.5 million in 2023, then increased by 2.24% to $3.6 million in 2024.
  • Its Depreciation and Depletion stands at $3.6 million for Q1 2024, versus $3.5 million for Q4 2023 and $3.6 million for Q3 2023.